Abstract:It is now little disputed that most if not all cancer cells express antigens that can be recognized by specific CD8(+) T lymphocytes. However, a central question in the field of anti-tumor immunity is why such antigen-expressing tumors are not spontaneously eliminated by the immune system. While in some cases, this lack of rejection may be due to immunologic ignorance, induction of anti-tumor T-cell responses in many patients has been detected in the peripheral blood, either spontaneously or in response to vaccination, without accompanying tumor rejection. These observations argue for the importance of barriers downstream from initial T-cell priming that need to be addressed to translate immune responses into clinical tumor regression. Recent data suggest that the proper trafficking of effector T cells into the tumor microenvironment may not always occur. T cells that do effectively home to tumor metastases are often found to be dysfunctional, pointing toward immunosuppressive mechanisms in the tumor microenvironment. T-cell anergy due to insufficient B7 costimulation, extrinsic suppression by regulatory cell populations, inhibition by ligands such as programmed death ligand-1, metabolic dysregulation by enzymes such as indoleamine-2,3-dioxygenase, and the action of soluble inhibitory factors such as transforming growth factor-beta have all been clearly implicated in generating this suppressive microenvironment. Identification of these downstream processes points to new therapeutic targets that should be manipulated to facilitate the effector phase of anti-tumor immune responses in concert with vaccination or T-cell adoptive transfer.

Immunological hide-and-seek: epigenetically reprogrammed cancer cells and the dynamics of CD8+ T cells

Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy

Tumor Immune Checkpoints and Their Associated Inhibitors

CD8+ T cell-based cancer immunotherapy

Navigating the Immune Maze: Pioneering Strategies for Un-shackling Cancer Immunotherapy Resistance

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets

Immune resistance orchestrated by the tumor microenvironment

Targeting the epigenome to reinvigorate T cells for cancer immunotherapy.

The Interplay Between Epigenetic Regulation and CD8+ T Cell Differentiation/Exhaustion for T Cell Immunotherapy

Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies

Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment

Immunocytes interact directly with cancer cells in the tumor microenvironment: one coin with two sides and future perspectives

Investigating T Cell Immunity in Cancer: Achievements and Prospects

Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells

Cracking the Codes behind Cancer Cells' Immune Evasion

The Interplay between T Cells and Cancer: The Basis of Immunotherapy

Immune responses and immunotherapeutic approaches in the treatment against cancer

Immunosuppressive Cells in Cancer: Mechanisms and Potential Therapeutic Targets

The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment